Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations

Future Science OA

Jasmine A McQuerry¹  Ziad Khan¹  Rebecca Pharaon¹  Yuan Yuan¹  Jeremy Fricke¹  Raju K Pillai¹  Andrea Bild¹  Erminia Massarelli¹  Isa Mambetsariev²  Marwan Fakih²  Marianna Koczywas²  Susan E Yost²  Leonidas Arvanitis²  Martin Sattler²  Ravi Salgia²  Tamara Mirzapoiazova²  Karen L Reckamp²  Sumanta K Pal³  Prakash Kulkarni³ 

[1] Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA;;1Department of Medical Oncology &4Department of Pathology, City of Hope National Medical Center, Duarte, CA 91010, USA;

关键词: immune markers;    MET;    NanoString;    solid tumors;    targeted therapy;   

DOI  :  10.2144/fsoa-2020-0159

来源: DOAJ

【 摘 要 】

The implication of MET alterations in solid tumors and the immune microenvironment remains elusive. Formalin-fixed, paraffin-embedded samples of 21 patients with solid tumors harboring MET alterations were used for immunohistochemical staining. Extracted RNA was analyzed with the NanoString nCounter human PanCancer immune profiling panel (NanoString Technologies, Inc., WA, USA). Patients were diagnosed with lung (n = 10), breast (n = 5), genitourinary (n = 3) or colorectal cancer (n = 3). Eleven had a MET missense mutation, four had an exon 14 splice site mutation and six had MET amplification. CD6, CCL19, CD40LG, XCR1, MAGEA1, ATM and CCL19 genes were significantly differentially expressed in MET-altered cancers. MET alterations may have a role in various solid tumors as potential therapeutic targets and combination therapy candidates with immune checkpoint inhibitors.

【 授权许可】

Unknown